Proactive Pharmaceutical Care Interventions Improve Patients' Adherence to Lipid-Lowering Medication

Annals of Pharmacotherapy

Volumn 47, Issue 11, 2013, Pages 1448-1456

  Stuurman Bieze, Ada G G ^a   Hiddink, Eric G ^b   van Boven, Job F M ^c   Vegter, Stefan ^c  

^a West Pharmacy   (Netherlands)

^b Stichting Health Base   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

adherence; discontinuation; lipid lowering drugs; pharmaceutical care; pharmacist intervention; statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; EZETIMIBE; FLUINDOSTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DRUG DEPENDENCE; DRUG PROGRAM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; MYALGIA; OUTCOME ASSESSMENT; PATIENT COUNSELING; PATIENT MONITORING; PATIENT SATISFACTION; PHARMACEUTICAL CARE; PHARMACIST ATTITUDE; PHARMACY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT REFUSAL;

ADHERENCE; DISCONTINUATION; LIPID-LOWERING DRUGS; PHARMACEUTICAL CARE; PHARMACIST INTERVENTION; STATINS;

COMMUNITY PHARMACY SERVICES; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; NETHERLANDS; PATIENT COMPLIANCE; PATIENT DROPOUTS; PATIENT SATISFACTION; PROSPECTIVE STUDIES;

EID: 84889054576     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013501146     Document Type: Article

References (37)

1. NHG standaard Cardiovasculair risiscomanagement.Huisarts Wet. 2012;55:14-18.
2. NHG standaard Diabetes mellitus.Huisarts Wet. 2006;49:137-152.
3. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.Lancet. 2002;360:7-22.
4. Shepherd J,Cobbe SM,Ford I,et al.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.N Engl J Med. 1995;333:1301-1307.
5. Pedersen TR,Kjekshus J,Berg K,et al.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994.Atheroscler Suppl. 2004;5:81-87.
6. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts.Lancet. 1995;346:1647-1653.
7. Herings R,Leufkens H,Heerdink E,Klungel O,Breekveldt-Postma NChronische Farmacotherapie Voortgezet. Een onderzoek naar de omvang, determinanten en mogelijke economische consequenties van het vroegtijdig afbreken van chronische farmacotherapie. Utrecht, Netherlands: PHARMO Instituut; 2002:.
8. Naderi SH,Bestwick JP,Wald DS.Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients.Am J Med. 2012;125:882,7.e1.
9. Cramer JA,Benedict A,Muszbek N,Keskinaslan A,Khan ZM.The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review.Int J Clin Pract. 2008;62:76-87.
10. Benner JS,Glynn RJ,Mogun H,Neumann PJ,Weinstein MC,Avorn J.Long-term persistence in use of statin therapy in elderly patients.JAMA. 2002;288:455-461.
11. Catalan VS,LeLorier J.Predictors of long-term persistence on statins in a subsidized clinical population.Value Health. 2000;3:417-426.
12. Jackevicius CA,Mamdani M,Tu JV.Adherence with statin therapy in elderly patients with and without acute coronary syndromes.JAMA. 2002;288:462-467.
13. Lemstra M,Blackburn D.Nonadherence to statin therapy: discontinuation after a single fill.Can J Cardiol. 2012;28:567-573.
14. Penning-van Beest FJ,Termorshuizen F,Goettsch WG,Klungel OH,Kastelein JJ,Herings RM.Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study.Eur Heart J. 2007;28:154-159.
15. van der Elst ME,Bouvy ML,de Blaey CJ,de Boer A.Effect of drug combinations on admission for recurrent myocardial infarction.Heart. 2007;93:1226-1230.
16. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study.Eur Heart J. 1997;18:1718-1724.
17. Rasmussen JN,Chong A,Alter DA.Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction.JAMA. 2007;297:177-186.
18. Eussen SR,van der Elst ME,Klungel OH,et al.A pharmaceutical care program to improve adherence to statin therapy: a randomized controlled trial.Ann Pharmacother. 2010;44:1905-1913.
19. Vrijens B,Belmans A,Matthys K,de Klerk E,Lesaffre E.Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin.Pharmacoepidemiol Drug Saf. 2006;15:115-121.
20. Taitel M,Jiang J,Rudkin K,Ewing S,Duncan I.The impact of pharmacist face-to-face counseling to improve medication adherence among patients initiating statin therapy.Patient Prefer Adherence. 2012;6:323-9.
21. Lee JK,Grace KA,Taylor AJ.Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial.JAMA. 2006;296:2563-2571.
22. Van Wijk BL,Klungel OH,Heerdink ER,de Boer A.Effectiveness of interventions by community pharmacists to improve patient adherence to chronic medication: a systematic review.Ann Pharmacother. 2005;39:319-328.
23. Pharmaceutical Care Practice: The Clinician's Guide. 2nd ed.New York, NY: McGraw-Hill; 2004.Cipolle RJStrand LMMorley PC, ed. New York, NY: McGraw-Hill; 2004:.
24. Stuurman-Bieze AGG,Hiddink EG.Pharmaceutical care interventions, initiated by computerized drug prescription monitoring, improve drug compliance [article in Dutch].Pharm Weekbl Sci. 2010;4:128-135.
25. Boven van JFM,Hiddink EG,Stuurman-Bieze AGG,Postma MJ,Vegter S.Structured medication surveillance for improving adherence to bisphosphonate therapy offers perspectives for cost-effective pharmaceutical care [article in Dutch].Pharm Weekbl Sci. 2011;5:160-166.
26. Nederlandse Apotheek Norm (NAN). http://www.knmp.nl/organisatie-regelgeving/normen-en-richtlijnen/normen/nederlandse-apotheek-norm-nan. Accessed August 1, 2013.
27. van Hunsel F,Passier A,van Grootheest K.Comparing patients' and healthcare professionals' ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an example.Br J Clin Pharmacol. 2009;67:558-564.
28. Evans CD,Eurich DT,Lamb DA,et al.Retrospective observational assessment of statin adherence among subjects patronizing different types of community pharmacies in Canada.J Manag Care Pharm. 2009;15:476-484.
29. Yeaw J,Benner JS,Walt JG,Sian S,Smith DB.Comparing adherence and persistence across 6 chronic medication classes.J Manag Care Pharm. 2009;15:728-740.
30. Stuurman-Bieze AGG,Kokenberg ME,Tobi H,et al.Complex pharmaceutical care intervention in pulmonary care: part B. Patient opinion and process survey.Pharm World Sci. 2005;27:385-392.
31. Schirm E,Monster TB,de Vries R,van den Berg PB,de Jong-van den Berg LT,Tobi H.How to estimate the population that is covered by community pharmacies? An evaluation of two methods using drug utilisation information.Pharmacoepidemiol Drug Saf. 2004;13:173-179.
32. Tobi H,van den Berg P,de Jong-van den Berg LT.The interaction database: synergy of science and practice in pharmacy.Med Data Anal. 2000:206-211.
33. van Boven JF,de Boer PT,Postma MJ,Vegter S.Persistence with osteoporosis medication among newly-treated osteoporotic patients [published online April 11, 2013].J Bone Miner Metab.
34. Vegter S,Nguyen NH,Visser ST,de Jong-van den Berg LT,Postma MJ,Boersma C.Compliance, persistence, and switching patterns for ACE inhibitors and ARBs.Am J Manag Care. 2011;17:609-616.
35. Blom A,Hugtenburg J,Post C.Begeleiding tweede uitgifte nuttig voor de patiënt.Pharm Weekbl Sci. 2007;1:156-159.
36. Lau HS,de Boer A,Beuning KS,Porsius A.Validation of pharmacy records in drug exposure assessment.J Clin Epidemiol. 1997;50:619-625.
37. Oosterhof P,Boven van JFM,Hiddink EG,Stuurman-Bieze AGG,Postma MJ,Vegter S.Costeffectiveness of a pharmaceutical care intervention program to increasing statin adherence for secondary prevention.Value Health. 2011;14:A379.